Navigation Links
AbbVie Declares Dividend and Announces Share Repurchase Program
Date:2/15/2013

NORTH CHICAGO, Ill., Feb. 15, 2013 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend and also authorized a share repurchase program of up to $1.5 billion of the Company's outstanding common stock.

The cash dividend of $0.40 per share is payable May 15, 2013 to stockholders of record at the close of business on April 15, 2013.  AbbVie was named to the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.  AbbVie was included as a result of the Index's change in its treatment of spin-off companies.

The share repurchase authorization, which is effective immediately, is expected to be completed over a multi-year period and purchases may be made from time to time in management's discretion. The share repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

<
'/>"/>
SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
2. BioMed Realty Trust Declares Second Quarter 2012 Common Stock And Preferred Stock Dividends
3. Techne Corporation Declares Dividend
4. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
5. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
6. PDL BioPharma Completes Regular Quarterly Dividend Payment
7. Amgen Announces 2012 First Quarter Dividend
8. Osteologix Announces Dividend
9. Amgen Announces 2012 Third Quarter Dividend
10. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ... initiative to create the next generation of fertilizers and production technologies, with initial financial ... ... -- IFDC is launching the Virtual Fertilizer Research Center (VFRC), a global ...
... , ... ... ... , ...
... ... ... ... ...
Cached Biology Technology:IFDC Launches Virtual Fertilizer Research Center 2IFDC Launches Virtual Fertilizer Research Center 3IFDC Launches Virtual Fertilizer Research Center 4IFDC Launches Virtual Fertilizer Research Center 5Icahn Nominates 4 to Genzyme Slate 2Icahn Nominates 4 to Genzyme Slate 3Icahn Nominates 4 to Genzyme Slate 4Icahn Nominates 4 to Genzyme Slate 5Icahn Nominates 4 to Genzyme Slate 6Icahn Nominates 4 to Genzyme Slate 7Icahn Nominates 4 to Genzyme Slate 8Icahn Nominates 4 to Genzyme Slate 9Icahn Nominates 4 to Genzyme Slate 10Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 2Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 3Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 4Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 5Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 6
(Date:4/16/2014)... U.S. and beyond will convene in Lincoln, Nebraska, USA, ... existing science, and explore the unique geologic and historic ... applied geology, paleontology, and mid-continent geology. Events include a ... Kirk Johnson, Sant Director of the Smithsonian National Museum ... by the University of Nebraska-Lincoln. Lincoln is located near ...
(Date:4/16/2014)... Our ability to store memories improves during childhood, ... its connections with prefrontal and parietal cortices. New ... brain regions develop at this crucial time. Eventually, ... emerge in the transition into and during adolescence ... , Located deep in the middle of the ...
(Date:4/16/2014)... Martin Prechtl, Leo Heim and their colleagues at the ... new method of generating hydrogen using water and formaldehyde. ... interest when it comes to fuel cell technologies. The ... production using water and formaldehyde", have recently been published ... other applications, the new approach can be used to ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4How kids' brain structures grow as memory develops 2
... the diaphragm muscles has received approval from the Food and ... Sclerosis (ALS), also known as Lou Gehrig,s disease. The ... patients breathe longer without the aid of a ventilator. ... Medical Center who helped develop and test DPS and who ...
... in the October 2011 print issue of The FASEB ... what kicks off the process that causes varicose veins. In ... binds to DNA to control gene function (called "transcription factor ... of proteins that significantly affect the development of varicose veins. ...
... work of a team of scientists at Cold Spring Harbor ... way to overcome one of the major technical obstacles preventing ... addressed successfully by novel drugs. The target is ... long known to be an important player in the signaling ...
Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Scientists discover the proteins that control development of varicose veins 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 3Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 4